

























































published: 14 November 2013
doi: 10.3389/fimmu.2013.00374
Complementarity of binding motifs is a general property of
HLA-A and HLA-B molecules and does not seem to effect
HLA haplotype composition
Xiangyu Rao1, Rob J. De Boer 1, Debbie van Baarle2, Martin Maiers3 and Can Kesmir 1*
1 Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands
2 Immunology Department,Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands
3 National Marrow Donor Program, Minneapolis, MN, USA
Edited by:
Michal Or-Guil, Humboldt University
Berlin, Germany
Reviewed by:
Edward John Collins, The University
of North Carolina at Chapel Hill, USA
Fernando A. Arosa, University of Beira
Interior, Portugal
Dmitriy M. Chudakov, M.M.
Shemyakin andYu.A. Ovchinnikov
Institute of Bioorganic Chemistry of
the Russian Academy of Sciences,
Russia
*Correspondence:
Can Kesmir , Theoretical Biology and
Bioinformatics, Utrecht University,
Padualaan 8, 3584 CH Utrecht,
Netherlands
e-mail: c.kesmir@uu.nl
Different human leukocyte antigen (HLA) haplotypes (i.e., the specific combinations of HLA-
A, -B, -DR alleles inherited together from one parent) are observed in different frequencies
in human populations. Some haplotypes, like HLA-A1-B8, are very frequent, reaching up to
10% in the Caucasian population, while others are very rare. Numerous studies have iden-
tified associations between HLA haplotypes and diseases, and differences in haplotype
frequencies can in part be explained by these associations: the stronger the association
with a severe (autoimmune) disease, the lower the expected HLA haplotype frequency.The
peptide repertoires of the HLA molecules composing a haplotype can also influence the fre-
quency of a haplotype. For example, it would seem advantageous to have HLA molecules
with non-overlapping binding specificities within a haplotype, as individuals expressing
such an haplotype would present a diverse set of peptides from viruses and pathogenic
bacteria on the cell surface. To test this hypothesis, we collect the proteome data from
a set of common viruses, and estimate the total ligand repertoire of HLA class I haplo-
types (HLA-A-B) using in silico predictions. We compare the size of these repertoires to
the HLA haplotype frequencies reported in the National Marrow Donor Program (NMDP).
We find that in most HLA-A and HLA-B pairs have fairly distinct binding motifs, and that the
observed haplotypes do not contain HLA-A and -B molecules with more distinct binding
motifs than random HLA-A and HLA-B pairs. In addition, the population frequency of a hap-
lotype is not correlated to the distinctness of its HLA-A and HLA-B peptide binding motifs.
These results suggest that there is a not a strong selection pressure on the haplotype level
favoring haplotypes having HLA molecules with distinct binding motifs, which would result
the largest possible presented peptide repertoires in the context of infectious diseases.
Keywords: haplotypes, HLA antigens, selection, genetic, peptide binding, bioinformatics, computational biology
INTRODUCTION
The human leukocyte antigen (HLA) genes are the most poly-
morphic coding loci known in humans. The HLA gene cluster is
located on the major histocompatibility complex (MHC) on chro-
mosome 6, and contains over 200 genes. The two groups of loci
that contain the MHC class I and II genes dictating T cell responses
are the most polymorphic. It is widely accepted that this variability
is maintained by balancing selection, as individuals that are het-
erozygous in their HLA class I and II loci seem to have a better
outcome in infections diseases [see e.g., for HIV-1 (1)]. In line
with this, it has been demonstrated that in several species, and up
to a certain extent in humans, females prefer to mate with males
having a dissimilar HLA to increase the chance of their offspring
to survive infectious diseases (2, 3). We have argued that the het-
erozygous advantage is on its own not enough to maintain such a
large degree of polymorphism, and that the frequency dependent
co-evolution with pathogens should also play a major role (4).
On the functional level the HLA polymorphism seems to be
much smaller. It is well established that MHC class II molecules
have largely overlapping peptide repertoires [see e.g., (5)]. In the
last few years we and others showed this to be also true for class I
alleles (6–9). This promiscuous peptide binding is not limited to
the alleles within each locus, and extends to alleles from different
MHC class I loci (7, 9). This property has important evolutionary
consequences as heterozygous individuals carrying genetically dif-
ferent HLA molecules that nevertheless have overlapping peptide
repertoires should have a diminished heterozygous advantage.
Recombinations occur frequently in the HLA region and they
generate novel HLA haplotypes (10). However, the number of hap-
lotypes found in human populations is far lower than the number
of alleles observed (11), suggesting that not all the HLA haplo-
types have the same chance of becoming established in human
populations. Indeed, different haplotypes occur with very dif-
ferent frequencies in different ethnic groups/subpopulations1,2.
1www.allelefrequencies.net
2www.nmdp.org
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The “usefulness” of HLA molecules is expected to play a role in
determining the haplotype frequencies: haplotypes carrying HLA
molecules that are protective for certain diseases are expected to
be present in relatively high frequencies in endemic areas. Indeed,
several HLA haplotype disease associations have been established,
e.g., in autoimmune diseases (12), squamous cell cervical cancer
(13) and recurrent aphthous stomatitis (14). Along these lines, one
can speculate that it should be advantageous to have MHC mol-
ecules with distinct binding specificities in a haplotype, because
such haplotypes would provide an individual with more epitopes
eliciting T cell responses during an infectious disease than hap-
lotypes containing HLA molecules with similar binding motifs.
This hypothesis is rather impossible to test experimentally, because
one needs to determine the total set of peptides presented by
a very large set of HLA molecules in cells infected by different
viruses. Such experiments (e.g., eluting peptides from HLA mole-
cules expressed by a cell) are typically done at small scales because
they are time consuming. Therefore, we here study the peptide
repertoires of HLA molecules that are estimated to be combined
in a haplotype (i.e., the ones with a strong linkage disequilibrium)
using an in silico approach. This approach unfortunately suffers
of two main limitations. First, the quality of the peptide-HLA
predictions differs between the loci. The quality of HLA-A and
HLA-B peptide binding predictions is very reliable. For the other
loci (HLA-C, HLA-DR, etc.) the predictions are of low quality (15),
and are therefore left out of this analysis. Second, having distinct
HLA binding motifs might also be important in the context of
cancer or autoimmunity, however, it is very complicated to deter-
mine the role of HLA haplotypes in these diseases. Therefore, we
perform our analysis explicitly for infectious diseases, and focus on
the peptides that can be presented from common viruses only. Still,
we think that our study is a first step to investigate the role of HLA
binding motifs in the evolution of HLA haplotype frequencies.
MATERIALS AND METHODS
NMDP DATA
All estimated HLA-A-B haplotype frequencies were downloaded
from the National Marrow Donor Program (NMDP) database,
which was established to develop and maintain a registry of
HLA-typed volunteer unrelated donors for patients requiring a
hematopoietic stem cell transplant (16)3. Four predominant US
ethnic and racial groups were included in this data set: European
Americans, African Americans, Asians, and Hispanic (17). Haplo-
type frequencies were estimated separately for each ethnic group
using an implementation of the expectation maximization (EM)
algorithm (18, 19).
The linkage disequilibrium, D, between two alleles in each
haplotype was expressed as the difference between the observed
and expected haplotype frequency: D= fAB−fAfB, where fAB is
the observed (estimated) haplotype frequency, fA is the allele fre-
quency of the HLA-A molecule in the haplotype and fB is the allele
frequency of the HLA-B molecule in this haplotype. D is easy to
calculate, but has the disadvantage of depending on the frequency
of the alleles. In order to overcome this drawback, the normalized
3http://bioinformatics.nmdp.org
measure, D′, was calculated a D′ = DDmax , where Dmax is the lesser
of fAB or (1− fA) (1− fB) when D< 0 and is the lesser of fA(1− fB)
or fB(1− fA) when D> 0. The advantage of this measure of dis-
equilibrium is that it ranges between −1 and 1, regardless of the
allelic frequencies in the sample.
∣∣D′∣∣ = 1 indicates complete LD
and D′= 0 corresponds to total absence of LD.
Linkage disequilibrium statistics were calculated for each
haplotype to identify the haplotypes that have a significantly
positive D′.
HLA LIGAND PREDICTION
To be able to perform our analysis for as many as possible HLA
molecules, we used NetMHCpan (15) to predict peptide-HLA
binding affinity. NetMHCpan assigns to each peptide-HLA pair
a predicted IC50 value, indicative of the predicted binding affin-
ity. To assess whether a peptide binds to an HLA molecule depends
on the choice of binding threshold, and the optimal threshold has
been discussed (20). If one assumes that all HLA molecules use a
fixed threshold, one can use the default threshold of 500 nM (21,
22), otherwise a 5000 nM threshold can be used to allow for the
comparison of more weakly binding peptides. However, using a
fixed threshold to define predicted binders result in large differ-
ences in the predicted repertoire sizes between HLA molecules.
For instance using a fixed threshold of 500 nM, the HLA reper-
toire sizes range between 20 and 6574 peptides for the viral set
listed in Table S2 in Supplementary Material. As such a variance
could introduce large biases in our analysis, we defined the 1%
top-ranking peptides as candidate binders for each HLA mole-
cule. This gives each HLA molecule the same ligand repertoire size
(i.e., 570 binders per HLA molecule for the viral set listed in Table
S2 in Supplementary Material). To check the consistency of our
results with respect to these parameters, we repeated every analy-
sis with the fixed threshold of 500 nM. All results presented below
were derived using the threshold of 1% to define candidate binders,
and remain similar for a fixed threshold, unless mentioned other-
wise. To test whether our results change if one were to use a much
larger data set, we also generated predicted binders using a much
larger set of viruses (see below), in which case each HLA molecule
had 60-fold more binders.
VIRAL DATA
The proteomes of 17 common human viruses were downloaded
from the European Bioinformatics Institute website4 (downloads
were made in October 2006, listed in Table S2 in Supplementary
Material) as the source of potential HLA ligands. To extend this
data set, we downloaded another set of proteomes (downloads
were made in October 2008)4 from viruses that are known to
infect mammalians (n= 904). We used the HLA-peptide binding
predictors (see above) to screen all possible unique virus-derived
9-mer peptides.
PEPTIDE REPERTOIRE OVERLAP
We define the peptide repertoire overlap between two HLA alleles
in the same HLA-A-B haplotype, Fp, as the fraction of overlap-
ping ligands between these two HLA class I molecules among
4www.ebi.ac.uk
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B , where A and B are the ligand
sets for HLA-A and -B molecule, respectively. Fp= 1 implies that
the HLA-A and HLA-B molecules belonging to the same hap-
lotype have the same epitope repertories while Fp= 0 indicates
completely different peptide repertoires for two HLA molecules.
RESULTS AND DISCUSSION
DETERMINING HLA-A-B HAPLOTYPES
The “true” HLA haplotypes can be determined either by mol-
ecular haplotyping or family-based segregation studies (23–25).
However, both approaches are expensive and laborious, and there-
fore, statistical methods are typically used to infer haplotypes from
datasets covering large population of individuals with known HLA
genotypes (26). Several methods have been proposed to infer HLA
haplotypes from genotype data, and in recent studies the perfor-
mance of two most commonly used approaches, EM algorithm
based (implemented in Arlequin V3.0), and the Bayesian algo-
rithm based (implemented in PHASEV2.1.1),have been compared
(27, 28). Unfortunately, neither of the methods could infer all
of the known haplotypes: incorrect haplotypes were estimated
in more than 30% of the cases. However, once the sample size
increases, the power of these statistical methods is expected to
increase tremendously.
National marrow donor program2 provides, to our knowl-
edge, the largest repository of HLA-typed donors. Here use of
statistical methods should become more reliable (16): for the
HLA-A-B haplotype, the total chromosome counts (2N) for the
four major ethnic groups exceeds 2000. On the NMDP webpage3,
the high-resolution allele and haplotype frequencies [estimated
by EM method, (18, 19)] are available (17). Focusing on HLA-A-B
haplotypes, the most common haplotypes found in US popula-
tion (separated into four main ethnic groups) are summarized
in Table 1 (adopted from bioinformatics.nmdp.org, December
2007 version). Alternatively Allele frequencies web server1, pro-
vides allele frequencies established in smaller, but probably better
defined studies (29).
In the NMDP database 660 possible haplotypes are reported
for European Americans. However, many of these haplotypes are
bound to be falsely predicted, e.g., due to the limited number of
individuals carrying particular combinations of specific HLA mol-
ecules. To decrease the amount of wrongly identified haplotypes
in our analysis, we apply a rather strict criterion for considering
a predicted haplotype as a “true” haplotype: we demand a posi-
tive LD value that is significantly different than zero (p< 0.01, see
Materials and Methods). This criterion decreases the number of
haplotypes to 60 for European Americans. These 60 haplotypes
are estimated to cover 58% of the population (see Table 2), i.e.,
current statistical methods and data sets (even the large reposi-
tories like NMDP) remain rather limited in providing the HLA
haplotype diversity of a population. For other ethnical groups, the
number of reliable haplotypes drops to 30–40 per ethnic group,
even though the number of possible haplotypes was the same or
higher (see Table 2 and footnote text 3). The population coverage
in non-European groups was lower, 30–40% of their respective
populations, possibly due to the lower number of individuals
with known HLA-typing. All together we detected 120 reliable
unique haplotypes by summing over these ethnical groups (the
Table 1 | Occurrences of the three most common HLA-A-B frequency
ranked haplotypes in four major ethnic groups in US (adopted from
bioinformatics.nmdp.org).
EUR AFA API HIS
HLA-A HLA-B F (%) Rank F (%) Rank F (%) Rank F (%) Rank
0101 0801 9.55 1 1.50 6 0.41 46 2.21 2
0201 4402 5.70 3 1.33 9 0.17 130 1.94 4
0201 4501 0.05 200 1.66 3 – – 0.23 105
0201 5101 2.00 9 0.61 26 0.91 25 2.20 3
0207 4601 – – – – 3.34 2 – –
0301 0702 6.01 2 1.73 2 0.26 82 1.92 5
2902 4403 2.38 7 1.08 15 0.03 433 2.54 1
3001 4201 – – 2.96 1 – – 0.40 50
3303 4403 – – 0.09 261 2.94 3 0.16 156
3303 5801 0.08 162 0.28 88 4.53 1 0.10 230
EUR, Caucasian; AFA, African; API, Asian; HIS, Hispanic. F stands for population
frequency in percentages.
Table 2 | Numbers of different haplotypes with a significantly positive
LD in four major US ethnic groups.





Population coverage in percentages is given within parenthesis.
full list of haplotypes can be found in Table S1 in Supplementary
Material).
PEPTIDE REPERTOIRE OF AN HAPLOTYPE
Having identified the HLA-A-B haplotypes for the US popula-
tion, we next estimated the overlaps between peptide repertoires
of HLA-A and -B molecules that belong to the same haplotype.
We used an in silico approach and predicted the peptide reper-
toire of all HLA-A and HLA-B alleles that are part of the 120
predicted haplotypes, using the proteomes of common viruses
(see Table S2 in Supplementary Material) and HLA-peptide bind-
ing predictor NetMHCpan (15, 30) (see Materials and Methods).
NetMHCpan is the only prediction system available right now that
can reliably predict the peptide binding affinities for the large set
of HLA-A and HLA-B molecules we are taking into account in
this study. The analysis of the 120 significant haplotypes demands
predictions for 39 HLA-A and 63 HLA-B molecules. This predic-
tor assigns an IC50 value to each peptide-HLA pair, which can
be used as a predicted binding affinity. Using the widely accepted
IC50 value of 500 nM as a threshold to distinguish binders from
non-binders, generated a large variation in the predicted reper-
toire sizes of different HLA molecules (20–6574 peptides for the
viral set listed in Table S2 in Supplementary Material), which could
strongly bias our results. As the physiologically relevant IC50 val-
ues are difficult to estimate for each HLA molecule, we have chosen
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a simplified approach and define the peptide repertoire as the top
1% peptides with the highest HLA binding affinities for each HLA
molecule. This approach removes the potential bias introduced
by different repertoire sizes, but ignores the fact that some HLA
molecules can be more specific than others, and therefore present
much fewer peptides.
The unique haplotypes listed in Table S1 in Supplementary
Material have an average peptide overlap of 1.1% (with a standard
deviation of 1.8%, and a median of 0.44%) using top 1% thresh-
old. The distribution of the overlaps is given in Figure 1A, and
varies somewhat among the haplotypes. Out of 120 haplotypes,
36 (30%) have non-overlapping peptide repertoires, at least for
the common viruses that we tested (see Table S1 in Supplemen-
tary Material). Only for five haplotypes is the repertoire overlap
higher than 5%, and HLA-A0101-B1517 with an overlap of 11.8%
is the highest. HLA-A0101-B1517 is a rare haplotype and occurs
only in Asian Americans with a population frequency of 0.4%.
To test whether or not rare haplotypes tend to have larger over-
laps than common haplotypes, we weighted the overlaps found in
Figure 1A with the population frequency of the HLA-A-B hap-
lotypes (Figure 1B). Since the weighted overlaps remain very
similar to the unweighted overlaps (Figures 1A,B), there is no
evidence for a trend of rare haplotypes having the largest overlaps.
In line with this, the frequency of a haplotype is only weakly cor-
related with the degree of peptide overlap between the haplotype’s
HLA-A and HLA-B molecules (r =−0.08, p= 0.4, Spearman rank
correlation). Apparently, there is no selection pressure increasing
the frequency of the haplotypes with a small peptide repertoire
overlap.
These results were obtained using the top 1% peptides with
the highest HLA binding affinities as the set of presented peptides
per molecule. Using the set of common viruses listed in Table
S2 in Supplementary Material, this threshold results in approxi-
mately 570 predicted binders per HLA molecule. To test whether
the results presented in Figure 1A would be sensitive to the num-
ber of peptides, we collected proteomes for a much larger set
of mammalian viruses (n= 904), which contains approximately
three million unique peptides of nine amino acids. Using the same
1% threshold for this larger set, we predict for each HLA mole-
cule the extended peptide repertoire and calculate the overlaps as
explained before. The distribution of the overlaps hardly changes
despite the fact that we enlarged the presented peptide repertoire
60-fold per molecule (see Figure S1 in Supplementary Material).
As the results presented in Figure 1A seem fairly insensitive to the
number of peptides used, we perform the rest of the analysis on
the small data set of common viruses.
To test whether or not HLA binding motifs affect haplo-
type compositions requires comparison of the peptide overlaps
of “true” haplotypes with those of “random” haplotypes. To do
this, we reshuffled HLA-A and HLA-B molecules in the 120 “true”
haplotypes to calculate an expected peptide repertoire overlap for
randomly made haplotypes. Although the HLA molecules in ran-
dom haplotypes can have overlaps up to 28% in their peptide
repertoires (see Figure 1C and results not shown), the distribution
of the overlaps is not significantly different from the distribution
given in Figure 1A. The set of random haplotypes was gener-
ated 100 times, and in none of these cases was the distribution
significantly different from the one given in Figure 1A (using a
Kolmogorov–Smirnov test). Finally, we calculated a weighted pep-
tide repertoire overlap for the random haplotypes by assuming that
the frequency of a random haplotype is simply the multiplication
of the frequency of their HLA-A and HLA-B alleles (i.e., assuming
a complete lack of linkage disequilibrium). Again, the distribution
of weighted overlap of random haplotypes (Figure 1D) is not dif-
ferent from that of the real haplotypes (Figure 1B). Taken together,
these results suggest that HLA-A and -B in pairs in general have
distinct peptide binding preferences, and that a small overlap is not
a unique property of the HLA molecules having a strong linkage
disequilibrium.
The overlap distribution presented in Figure 1 seems to be in
contradiction with earlier results, which estimated cross loci pep-
tide overlaps of 23–44% (7, 9). However, this overlap was estimated
at the population level, i.e., these percentages reflect the fraction
of the peptide repertoire of an HLA-A molecule which is also
expected to be presented by at least one HLA-B molecule in the
population (and vice versa). Within an individual having maxi-
mally two different HLA-A and HLA-B molecules, the overlaps
should remain much lower than the population based overlaps. In
addition, one needs to realize that the low overlaps presented in
Figure 1 depend on the threshold used to define the peptide reper-
toire of an HLA molecule. When we use a higher threshold of 2
or 5% the average overlap increases to 2.3 and 5.9%, respectively
(with the standard threshold of 1%, the average overlap was 1.1%,
see above). However, the choice of the threshold hardly affects our
main result, namely that the HLA-A and -B pairs that are in a
linkage disequilibrium do not have more distinct binding motifs
than random HLA-A/B pairs (Figure 1).
CONCLUSION
We hypothesized that it should be advantageous to have HLA mol-
ecules with distinct binding specificities combined in a haplotype,
because during a viral infection such haplotypes would give an
individual a larger epitope repertoire than haplotypes contain-
ing HLA molecules with similar binding motifs during a viral
infection. To test this hypothesis, we used the high-resolution data
available in the NMDP database on haplotype frequencies, and
employed state of the art peptide-HLA binding prediction tools.
We find that for all the haplotypes we could reliably identify in the
US population, their HLA-A and HLA-B molecules present largely
distinct set of peptides (Figure 1A). However, this turned out to
be a generic property of HLA-A and HLA-B molecules: when we
compared random HLA-A and -B pairs we find a very similar
distribution of the presented peptide overlaps (Figure 1C). More-
over, there is no evidence for selection as there is no correlation
between the population frequency of the HLA-A-B haplotypes
and the overlap in the peptide repertoires of their HLA-A and
HLA-B molecules. Taken together, these results suggest the com-
plementarity of binding motifs is a general property of HLA-A
and HLA-B molecules, and that complementarity does not affect
the HLA haplotype composition. We were not able to specifically
test the effect of complimentary binding motifs in the context
of autoimmunity and cancer, as for both cases it remains unclear
which set of human proteins should be taken as possible auto anti-
gens. Complimentary binding motifs are expected to increase the
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FIGURE 1 | Distribution of the presented peptide overlap (given in
percentages, see Materials and Methods) between HLA-A and
HLA-B molecules belonging to the same haplotype. (A) The
distribution of the peptide overlaps for the 120 unique haplotypes we
identified in the US population. (B) The distribution in A is weighted with
the frequency of the haplotype in the population. If a haplotype was
found in more than one ethnicity in US, we have taken the maximum
frequency into account, normalizing the frequencies such that the sum
remains one. In (C) we plot the overlaps found in artificially generated
haplotypes (created by reshuffling the HLA-A and -B molecules from the
120 unique haplotypes). This plot is representative of 100 sets of
artificially generated haplotypes. (D) The weighted peptide overlaps for
the artificial haplotypes, where we estimate the frequency of the
haplotype as the multiplication of the frequency of HLA-A and HLA-B
molecule in the population (normalized to let the sum of the frequencies
of the artificial haplotypes remain one).
number of potential self antigens, which could increase the risk
of autoimmunity. Finally, the frequency of an HLA haplotype is
determined by complex interactions with many different factors,
one example is the correlation between birth weight and particular
haplotypes (31). Our results suggest that complimentary binding
motifs of HLA molecules during viral infections play a minor role,
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if any, compared to these other factors in the evolution of HLA
haplotype frequencies.
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